JP2014533960A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014533960A5 JP2014533960A5 JP2014542865A JP2014542865A JP2014533960A5 JP 2014533960 A5 JP2014533960 A5 JP 2014533960A5 JP 2014542865 A JP2014542865 A JP 2014542865A JP 2014542865 A JP2014542865 A JP 2014542865A JP 2014533960 A5 JP2014533960 A5 JP 2014533960A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- patient
- treatment
- egfr
- egfr inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims 19
- 206010028980 Neoplasm Diseases 0.000 claims 14
- 201000011510 cancer Diseases 0.000 claims 12
- 229940121647 egfr inhibitor Drugs 0.000 claims 12
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 238000011282 treatment Methods 0.000 claims 8
- 102000001301 EGF receptor Human genes 0.000 claims 5
- 108060006698 EGF receptor Proteins 0.000 claims 5
- 108091070501 miRNA Proteins 0.000 claims 5
- 239000002679 microRNA Substances 0.000 claims 5
- 206010009944 Colon cancer Diseases 0.000 claims 4
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 4
- 108091070395 Homo sapiens miR-31 stem-loop Proteins 0.000 claims 4
- 206010006187 Breast cancer Diseases 0.000 claims 3
- 208000026310 Breast neoplasm Diseases 0.000 claims 3
- 101000984753 Homo sapiens Serine/threonine-protein kinase B-raf Proteins 0.000 claims 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 3
- 102100027103 Serine/threonine-protein kinase B-raf Human genes 0.000 claims 3
- 201000005202 lung cancer Diseases 0.000 claims 3
- 208000020816 lung neoplasm Diseases 0.000 claims 3
- 239000013610 patient sample Substances 0.000 claims 3
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 claims 2
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 claims 2
- 238000011394 anticancer treatment Methods 0.000 claims 2
- 239000003153 chemical reaction reagent Substances 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 239000002525 vasculotropin inhibitor Substances 0.000 claims 2
- YXTKHLHCVFUPPT-YYFJYKOTSA-N (2s)-2-[[4-[(2-amino-5-formyl-4-oxo-1,6,7,8-tetrahydropteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid;(1r,2r)-1,2-dimethanidylcyclohexane;5-fluoro-1h-pyrimidine-2,4-dione;oxalic acid;platinum(2+) Chemical compound [Pt+2].OC(=O)C(O)=O.[CH2-][C@@H]1CCCC[C@H]1[CH2-].FC1=CNC(=O)NC1=O.C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 YXTKHLHCVFUPPT-YYFJYKOTSA-N 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- UZUUQCBCWDBYCG-UHFFFAOYSA-N Mitomycin B Natural products O=C1C(OC)=C(C)C(=O)C2=C1C(COC(N)=O)C1(O)N2CC2C1N2C UZUUQCBCWDBYCG-UHFFFAOYSA-N 0.000 claims 1
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 claims 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 238000001574 biopsy Methods 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- JYEFSHLLTQIXIO-SMNQTINBSA-N folfiri regimen Chemical compound FC1=CNC(=O)NC1=O.C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1.C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 JYEFSHLLTQIXIO-SMNQTINBSA-N 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- UZUUQCBCWDBYCG-DQRAMIIBSA-N mitomycin B Chemical compound O=C1C(OC)=C(C)C(=O)C2=C1[C@H](COC(N)=O)[C@]1(O)N2C[C@H]2[C@@H]1N2C UZUUQCBCWDBYCG-DQRAMIIBSA-N 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 238000003757 reverse transcription PCR Methods 0.000 claims 1
- 239000000523 sample Substances 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11306568 | 2011-11-25 | ||
| EP11306568.4 | 2011-11-25 | ||
| EP12306042 | 2012-08-31 | ||
| EP12306042.8 | 2012-08-31 | ||
| PCT/EP2012/073535 WO2013076282A1 (en) | 2011-11-25 | 2012-11-23 | A method for predicting responsiveness to a treatment with an egfr inhibitor |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014533960A JP2014533960A (ja) | 2014-12-18 |
| JP2014533960A5 true JP2014533960A5 (enExample) | 2016-01-14 |
| JP6342329B2 JP6342329B2 (ja) | 2018-06-13 |
Family
ID=47297187
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014542865A Expired - Fee Related JP6342329B2 (ja) | 2011-11-25 | 2012-11-23 | Ｅｇｆｒ阻害剤による治療に対する応答性を予測するための方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US10400284B2 (enExample) |
| EP (1) | EP2783017B1 (enExample) |
| JP (1) | JP6342329B2 (enExample) |
| KR (1) | KR20140104419A (enExample) |
| CN (1) | CN104160038B (enExample) |
| AU (1) | AU2012342397B2 (enExample) |
| BR (1) | BR112014012495A2 (enExample) |
| CA (1) | CA2856594A1 (enExample) |
| MX (1) | MX2014006182A (enExample) |
| WO (1) | WO2013076282A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12704501B2 (en) | 2019-03-29 | 2026-08-11 | Rakuten Medical, Inc. | Methods for photoimmunotherapy and related biomarkers |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2931176A1 (en) * | 2013-11-26 | 2015-06-04 | Integragen | A method for predicting responsiveness to a treatment with an egfr inhibitor |
| KR101622454B1 (ko) | 2014-03-04 | 2016-05-18 | 연세대학교 산학협력단 | Egfr 티로신 키나아제 억제제에 대한 항암 치료 반응 예측 마커 |
| EP3131552B1 (en) * | 2014-04-16 | 2020-07-15 | Signal Pharmaceuticals, LLC | Methods for treating cancer using tor kinase inhibitor combination therapy |
| EP3000895A1 (en) * | 2014-09-26 | 2016-03-30 | Integragen | A method for predicting responsiveness to a treatment with an EGFR inhibitor |
| CN107850599B (zh) * | 2015-07-23 | 2021-02-09 | 新加坡国立大学 | Wbp2与her2作为共预后因子对患者分层以进行治疗 |
| EP3450555B1 (en) * | 2016-04-28 | 2020-11-18 | Denka Company Limited | Method for determining tolerance of cancer cell to epidermal growth factor receptor inhibitor |
| KR102251864B1 (ko) * | 2019-10-18 | 2021-05-14 | 지니너스 주식회사 | miR-320c를 유효성분으로 포함하는 백금계 항암제에 대한 삼중음성유방암 환자의 약물 반응성 예측용 바이오마커 조성물 |
| CN111798918A (zh) * | 2020-05-28 | 2020-10-20 | 中山大学孙逸仙纪念医院 | 一种免疫治疗疗效预测的血肿瘤突变算法及其构建方法 |
| CN111863159B (zh) * | 2020-06-01 | 2022-02-25 | 中山大学孙逸仙纪念医院 | 一种肿瘤免疫治疗疗效预测的列线图模型的建立方法 |
| WO2023165494A1 (en) * | 2022-03-01 | 2023-09-07 | Crown Bioscience (Suzhou) Inc. | Methods for determining cetuximab sensitivity in cancer patients |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2439402A1 (en) | 2001-03-02 | 2002-09-12 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Pcr method |
| RU2010120674A (ru) * | 2007-10-22 | 2011-11-27 | Шеринг Корпорейшн (US) | Полностью человеческие анти-vegf-антитела и способы их применения |
| WO2009080437A1 (en) | 2007-12-21 | 2009-07-02 | Exiqon A/S | Micro-rna based drug resistance analysis method |
| WO2010015538A2 (en) * | 2008-08-05 | 2010-02-11 | F. Hoffmann-La Roche Ag | Predictive marker for egfr inhibitor treatment |
| EP2419522A4 (en) | 2009-04-17 | 2012-10-31 | Glen Weiss | METHOD AND KITS FOR THE FORECASTING OF THERAPY RESULTS OF TYROSINE CHINESE INHIBITORS |
| US9051551B2 (en) * | 2009-11-24 | 2015-06-09 | The University Of Western Australia | Methods and compositions for increasing sensitivity to tyrosine kinase inhibitors |
| EP2563936B1 (en) * | 2010-04-29 | 2018-03-14 | Medical Prognosis Institute A/S | Methods and devices for predicting treatment efficacy |
-
2012
- 2012-11-23 BR BR112014012495A patent/BR112014012495A2/pt active Search and Examination
- 2012-11-23 MX MX2014006182A patent/MX2014006182A/es unknown
- 2012-11-23 CA CA2856594A patent/CA2856594A1/en not_active Abandoned
- 2012-11-23 AU AU2012342397A patent/AU2012342397B2/en not_active Ceased
- 2012-11-23 KR KR1020147014013A patent/KR20140104419A/ko not_active Ceased
- 2012-11-23 JP JP2014542865A patent/JP6342329B2/ja not_active Expired - Fee Related
- 2012-11-23 CN CN201280067832.4A patent/CN104160038B/zh not_active Expired - Fee Related
- 2012-11-23 WO PCT/EP2012/073535 patent/WO2013076282A1/en not_active Ceased
- 2012-11-23 EP EP12797814.6A patent/EP2783017B1/en not_active Not-in-force
- 2012-11-23 US US14/360,311 patent/US10400284B2/en not_active Expired - Fee Related
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12704501B2 (en) | 2019-03-29 | 2026-08-11 | Rakuten Medical, Inc. | Methods for photoimmunotherapy and related biomarkers |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Li et al. | Long intergenic noncoding RNA HOTAIR is overexpressed and regulates PTEN methylation in laryngeal squamous cell carcinoma | |
| Lipsyc et al. | Impact of somatic mutations on patterns of metastasis in colorectal cancer | |
| Go et al. | High MET gene copy number leads to shorter survival in patients with non-small cell lung cancer | |
| US20220170107A1 (en) | Phosphatidylinositol-3-kinase pathway biomarkers | |
| Shen et al. | microRNA expression profiles associated with survival, disease progression, and response to gefitinib in completely resected non-small-cell lung cancer with EGFR mutation | |
| JP2017516458A5 (enExample) | ||
| Zhao et al. | Circulating miRNAs is a potential marker for gefitinib sensitivity and correlation with EGFR mutational status in human lung cancers | |
| Jo et al. | Human papillomavirus infection as a prognostic factor in oropharyngeal squamous cell carcinomas treated in a prospective phase II clinical trial | |
| JP2017529852A5 (enExample) | ||
| Butz et al. | Elucidating mechanisms of sunitinib resistance in renal cancer: An integrated pathological-molecular analysis | |
| Stanitz et al. | Alteration of miRNA expression correlates with lifestyle, social and environmental determinants in esophageal carcinoma | |
| CN104160038A (zh) | 一种用于预测对采用egfr抑制剂的治疗的响应性的方法 | |
| Pan et al. | miR-566 functions as an oncogene and a potential biomarker for prognosis in renal cell carcinoma | |
| EP3198028B1 (en) | A method for predicting responsiveness to a treatment with an egfr inhibitor | |
| Zhou et al. | Long noncoding RNA ZFAS1 promotes hepatocellular carcinoma proliferation by epigenetically repressing miR-193a-3p. | |
| JP6489658B2 (ja) | 肝細胞癌において分子標的治療の感受性を増加させるための分析方法 | |
| Igglezou et al. | Kinetics of circulating levels of miR-195, miR-155 and miR-21 in patients with breast cancer undergoing mastectomy | |
| Cheng et al. | Anti-EGFR MoAb treatment in colorectal cancer: limitations, controversies, and contradictories | |
| Pickhard et al. | The response of head and neck squamous cell carcinoma to cetuximab treatment depends on Aurora kinase A polymorphism | |
| Loeschke et al. | Prognostic value of HMGA2, P16, and HPV in oral squamous cell carcinomas | |
| Schweiger et al. | Canine and human sarcomas exhibit predominant FGFR1 expression and impaired viability after inhibition of signaling | |
| Han et al. | EGFR and KRAS mutations and altered c-Met gene copy numbers in primary non-small cell lung cancer and associated stage N2 lymph node-metastasis | |
| An et al. | Association of E2F3 expression with clinicopathological features of Wilms’ tumors | |
| Wang et al. | A functional variant at miRNA-122 binding site in IL-1α 3′ UTR predicts risk of recurrence in patients with oropharyngeal cancer | |
| Yuxian et al. | Paired-like homeodomain transcription factor 2 strengthens chemoresistance in colorectal cancer by activating the Wnt/β-catenin axis. |